Educational content on VJOncology is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

Share this video  

ASCO 2025 | Metastatic hormone-sensitive prostate cancer highlights from ASCO 2025

Andrew Armstrong • 1 Jun 2025
ASCO 2025
Genitourinary Cancer Prostate Cancer
AMPLITUDE ARCHES IRONMAN STAMPEDE TALAPRO-2

Andrew Armstrong, MD, MS, Duke Cancer Institute, Durham, NC, discusses the key advancements in metastatic hormone-sensitive prostate cancer (mHSPC) presented at the 2025 American Society of Clinical Oncology (ASCO) meeting. He highlights several trials exhibiting the latest long-term data on precision medicine, novel therapeutic approaches, and the emerging role of artificial intelligence-driven biomarkers in the field. This interview took place at the 2025 ASCO meeting in Chicago, IL.

These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.

More from Andrew Armstrong

TulmiSTAR-01: tulmimetostat with luxdegalutamide in mCRPC
1:16
TulmiSTAR-01: tulmimetostat with luxdegalutamide in mCRPC
Andrew Armstrong • 26 Feb 2026
Implementing PCWG4 guidance to refine endpoints in prostate cancer
1:23
Implementing PCWG4 guidance to refine endpoints in prostate cancer
Andrew Armstrong • 26 Feb 2026
Trial design recommendations for prostate cancer: PCWG4 guidance
1:02
Trial design recommendations for prostate cancer: PCWG4 guidance
Andrew Armstrong • 26 Feb 2026
Assessing the long-term role of enzalutamide for mHSPC
1:23
Assessing the long-term role of enzalutamide for mHSPC
Andrew Armstrong • 1 Jun 2025

Related Videos

Treatment sequencing after EV plus pembrolizumab in metastatic bladder cancer
2:10
Treatment sequencing after EV plus pembrolizumab in metastatic bladder cancer
Tian Zhang • 1 Jun 2026
Highlights in ADCs for bladder cancer at ASCO 2026
1:29
Highlights in ADCs for bladder cancer at ASCO 2026
Tian Zhang • 1 Jun 2026
EV plus pembrolizumab improves perioperative outcomes in muscle-invasive bladder cancer
3:36
EV plus pembrolizumab improves perioperative outcomes in muscle-invasive bladder cancer
Tian Zhang • 1 Jun 2026
Drug repurposing and trial challenges in rare renal medullary carcinoma
3:11
Drug repurposing and trial challenges in rare renal medullary carcinoma
Pavlos Msaouel • 30 May 2026
The content of VJOncology is intended for healthcare professionals